Drug Profile
Ravoxertinib - Genentech
Alternative Names: GD0 994; GDC-0994; RG-7842Latest Information Update: 02 Aug 2019
Price :
$50
*
At a glance
- Originator Array BioPharma
- Developer Genentech
- Class Antineoplastics; Pyrazoles; Pyridines; Pyridones; Pyrimidines; Small molecules
- Mechanism of Action Extracellular signal-regulated MAP kinase inhibitors; Mitogen activated protein kinase 3 inhibitors; Mitogen-activated protein kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 30 Jul 2019 Array Biopharma has been acquired by Pfizer
- 28 Jul 2018 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in France (PO)